Latozinemab

GSK's phase III GLISTEN trial demonstrates linerixibat significantly improves cholestatic pruritus (relentless itch) in patients with primary biliary cholangitis, addressing a major quality of life concern.

The global bipolar depression market is projected to experience significant growth through 2034, driven by increasing prevalence, with the United States accounting for approximately 85% of the market share across major regions.

Alzamend Neuro partners with Tesla Dynamic Coils BV to develop a groundbreaking MRI head coil for measuring brain lithium levels across five Phase II clinical trials at Massachusetts General Hospital.

Alzamend Neuro will present at the Sequire Investor Summit on January 22, 2025, to update on clinical trial progress.

Alector anticipates topline data from the Phase 3 INFRONT-3 trial of latozinemab for frontotemporal dementia with a granulin gene mutation (FTD-GRN) by Q4 2025.